Journal
MOLECULAR GENETICS AND METABOLISM
Volume 119, Issue 1-2, Pages 37-43Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ymgme.2016.06.013
Keywords
CBP; p300; CREB-binding protein; Lysine acetyltransferase activity; Hematologic malignancies; Targeted therapy
Funding
- Alex's Lemonade Stand Foundation for Childhood Cancer Pediatric Oncology Student Training award
- Stanford University
- St. Baldrick's Foundation
- Bear Necessities Pediatric Cancer
- Ventura Foundation
- NIH [R01 HL75826]
- Maxfield Foundation
- SPARK program
- Child Health Research Institute Lucile Packard Foundation for Children's Health
- Leukemia and Lymphoma Society of America [SLP-8009-15]
- Pediatric Cancer Research Foundation
- Hyundai Hope On Wheels [02500CA]
- USC Parker Hughes Institute for Childhood Cancer Research/William Lawrence & Blanche Hughes Foundation
Ask authors/readers for more resources
CREB binding protein (CBP) and p300 are critical regulators of hematopoiesis through both their transcriptional coactivator and acetyltransferase activities. Loss or mutation of CBP/p300 results in hematologic deficiencies in proliferation and differentiation as well as disruption of hematopoietic stem cell renewal and the microenvironment. Aberrant lysine acetylation mediated by CBP/p300 has recently been implicated in the genesis of multiple hematologic cancers. Understanding the effects of disrupting the acetyltransferase activity of CBP/p300 could pave the way for new therapeutic approaches to treat patients with these diseases. (C) 2016 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
